More than nine in 10 physicians say that pre-authorization programs have a negative impact on patient outcomes, according to a recent survey by the American Medical Association (AMA). While insurers tend to authorize most requests, the process can be unwieldy – an administrative fiasco of recurring paperwork, phone calls and bureaucracy that can slow a patient's access to care. According to the AMA survey, which examined the experiences of 1,000 patient care physicians, 64 percent reported waiting at least one business day for prior authorization decisions from insurers--and 30 percent said they waited three business days or longer. Wait times for preauthorized medical care have consequences for patients. Imagine the efficiencies that could be achieved if the manual workflow of pre-authorizations could be lifted and replaced with automatic approvals that rely on artificial intelligence solutions.
President Donald Trump made rebuilding the U.S. armed forces a signature promise during the presidential campaign. But it's the GOP-controlled Congress that's leading the way by adding tens of billions of dollars to the annual defense policy bill to pay for active-duty troops, combat aircraft, and ships that he didn't request.
The Food and Drug Administration on Friday granted an emergency use authorization for the antiviral drug remdesivir for the treatment of COVID-19 following an initial trial that indicated it helped adults and children with severe disease. Remdesivir is produced by California pharmaceutical firm Gilead Sciences Inc. It initially was developed to treat Ebola. The emergency authorization allows the drug to be distributed in the United States and administered intravenously to patients with low blood oxygen levels or those needing oxygen therapy or more intensive breathing support like a mechanical ventilator. It was determined the drugs benefits outweigh its risks, which include possible liver damage, low blood pressure, nausea, vomiting, sweating and shivering.
The measure crafted by Rep. Barbara Lee of California, an anti-war Democrat and the only member of Congress to oppose the post-Sept. For example, American troops are battling an enemy --Islamic State militants -- that didn't exist 16 years ago in a country -- Syria -- that the U.S. didn't expect to be fighting in.
WASHINGTON – Top U.S. national security officials on Monday warned congressional Republicans and Democrats demanding a new war authorization that existing laws governing combat operations against terrorist groups are legally sufficient and that repealing them prematurely could signal the United States is backing away from the fight. During testimony before the Senate Foreign Relations Committee, Secretary of State Rex Tillerson and Defense Secretary Jim Mattis urged Congress to tread carefully. If lawmakers are compelled to replace the post-Sept. Tillerson and Mattis said President Donald Trump doesn't have permission from Congress to attack North Korea, but they indicated the U.S. Constitution gives him that power in certain circumstances where U.S. citizens and national security interests are being imminently threatened. The response troubled several Democrats who have expressed concerns over Trump's confrontational statements toward North Korea and its budding arsenal of nuclear weapons.